311 related articles for article (PubMed ID: 37435490)
1. Linsitinib, an IGF-1R inhibitor, attenuates disease development and progression in a model of thyroid eye disease.
Gulbins A; Horstmann M; Daser A; Flögel U; Oeverhaus M; Bechrakis NE; Banga JP; Keitsch S; Wilker B; Krause G; Hammer GD; Spencer AG; Zeidan R; Eckstein A; Philipp S; Görtz GE
Front Endocrinol (Lausanne); 2023; 14():1211473. PubMed ID: 37435490
[TBL] [Abstract][Full Text] [Related]
2. Potential involvement of the bone marrow in experimental Graves' disease and thyroid eye disease.
Gulbins A; Horstmann M; Keitsch S; Soddemann M; Wilker B; Wilson GC; Zeidan R; Hammer GD; Daser A; Bechrakis NE; Görtz GE; Eckstein A
Front Endocrinol (Lausanne); 2023; 14():1252727. PubMed ID: 37810891
[TBL] [Abstract][Full Text] [Related]
3. Fingolimod Improves the Outcome of Experimental Graves' Disease and Associated Orbitopathy by Modulating the Autoimmune Response to the Thyroid-Stimulating Hormone Receptor.
Plöhn S; Hose M; Schlüter A; Michel L; Diaz-Cano S; Hendgen-Cotta UB; Banga JP; Bechrakis NE; Hansen W; Eckstein A; Berchner-Pfannschmidt U
Thyroid; 2019 Sep; 29(9):1286-1301. PubMed ID: 31237525
[TBL] [Abstract][Full Text] [Related]
4. Targeting TSH and IGF-1 Receptors to Treat Thyroid Eye Disease.
Neumann S; Krieger CC; Gershengorn MC
Eur Thyroid J; 2020 Dec; 9(Suppl 1):59-65. PubMed ID: 33511086
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms in Graves Eye Disease: Apoptosis as the End Point of Insulin-Like Growth Factor 1 Receptor Inhibition.
Morshed SA; Ma R; Latif R; Davies TF
Thyroid; 2022 Apr; 32(4):429-439. PubMed ID: 34927457
[No Abstract] [Full Text] [Related]
6. Cytokines as Targets of Novel Therapies for Graves' Ophthalmopathy.
Fallahi P; Ferrari SM; Elia G; Ragusa F; Paparo SR; Patrizio A; Camastra S; Miccoli M; Cavallini G; Benvenga S; Antonelli A
Front Endocrinol (Lausanne); 2021; 12():654473. PubMed ID: 33935970
[TBL] [Abstract][Full Text] [Related]
7. Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves' orbitopathy.
Smith TJ; Hegedüs L; Douglas RS
Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):291-302. PubMed ID: 22632366
[TBL] [Abstract][Full Text] [Related]
8. An Early Wave of Macrophage Infiltration Intertwined with Antigen-Specific Proinflammatory T Cells and Browning of Adipose Tissue Characterizes the Onset of Orbital Inflammation in a Mouse Model of Graves' Orbitopathy.
Philipp S; Horstmann M; Hose M; Daser A; Görtz GE; Jesenek C; Flögel U; Hansen W; Bechrakis N; Banga JPS; Eckstein A; Berchner-Pfannschmidt U
Thyroid; 2022 Mar; 32(3):283-293. PubMed ID: 34779257
[No Abstract] [Full Text] [Related]
9. Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' disease and Graves' orbitopathy.
Marinò M; Rotondo Dottore G; Ionni I; Lanzolla G; Sabini E; Ricci D; Sframeli A; Mazzi B; Menconi F; Latrofa F; Vitti P; Marcocci C; Chiovato L
J Endocrinol Invest; 2019 Apr; 42(4):471-480. PubMed ID: 30132285
[TBL] [Abstract][Full Text] [Related]
10. Cre-loxP System-Based Mouse Model for Investigating Graves' Disease and Associated Orbitopathy.
Bao Y; Kim D; Cho YH; Ku CR; Yoon JS; Lee EJ
Thyroid; 2023 Nov; 33(11):1358-1367. PubMed ID: 37624749
[No Abstract] [Full Text] [Related]
11. [Pathogenesis of thyroid eye disease - does autoimmunity against the TSH receptor explain all cases?].
Wall JR; Lahooti H
Endokrynol Pol; 2011; 62 Suppl 1():1-7. PubMed ID: 22125104
[TBL] [Abstract][Full Text] [Related]
12. Pathogenesis of thyroid eye disease--does autoimmunity against the TSH receptor explain all cases?
Wall JR; Lahooti H
Endokrynol Pol; 2010; 61(2):222-7. PubMed ID: 20464711
[TBL] [Abstract][Full Text] [Related]
13. Clinical Management and Therapeutic Strategies for the Thyroid-Associated Ophthalmopathy: Current and Future Perspectives.
Mishra S; Maurya VK; Kumar S; Ankita ; Kaur A; Saxena SK
Curr Eye Res; 2020 Nov; 45(11):1325-1341. PubMed ID: 32567373
[TBL] [Abstract][Full Text] [Related]
14. Mouse model of Graves' orbitopathy induced by the immunization with TSHR A and IGF-1R α subunit gene.
Wu R; Li N; Wang X; Wang S; Tan J; Wang R; Zheng W
J Endocrinol Invest; 2024 Apr; ():. PubMed ID: 38662129
[TBL] [Abstract][Full Text] [Related]
15. Sphingolipids in thyroid eye disease.
Gulbins A; Görtz GE; Gulbins E; Eckstein A
Front Endocrinol (Lausanne); 2023; 14():1170884. PubMed ID: 37082124
[TBL] [Abstract][Full Text] [Related]
16. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease.
Tsui S; Naik V; Hoa N; Hwang CJ; Afifiyan NF; Sinha Hikim A; Gianoukakis AG; Douglas RS; Smith TJ
J Immunol; 2008 Sep; 181(6):4397-405. PubMed ID: 18768899
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic IGF-I receptor inhibition alters fibrocyte immune phenotype in thyroid-associated ophthalmopathy.
Fernando R; Caldera O; Smith TJ
Proc Natl Acad Sci U S A; 2021 Dec; 118(52):. PubMed ID: 34949642
[TBL] [Abstract][Full Text] [Related]
18. TSHR as a therapeutic target in Graves' disease.
Smith TJ
Expert Opin Ther Targets; 2017 Apr; 21(4):427-432. PubMed ID: 28127991
[TBL] [Abstract][Full Text] [Related]
19. TSH/IGF-1 Receptor Cross Talk in Graves' Ophthalmopathy Pathogenesis.
Krieger CC; Place RF; Bevilacqua C; Marcus-Samuels B; Abel BS; Skarulis MC; Kahaly GJ; Neumann S; Gershengorn MC
J Clin Endocrinol Metab; 2016 Jun; 101(6):2340-7. PubMed ID: 27043163
[TBL] [Abstract][Full Text] [Related]
20. A cyclic peptide significantly improves thyroid function, thyrotropin-receptor antibodies and orbital mucine /collagen content in a long-term Graves' disease mouse model.
Diana T; Ungerer M; Wüster C; Faßbender J; Li Z; Reimann A; Holthoff HP; Kanitz M; Kahaly GJ
J Autoimmun; 2021 Aug; 122():102666. PubMed ID: 34144327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]